Holen Sie sich die Stockscreener-App
4.61
2.44%
0.11
Handel nachbörslich:
4.61
Schlusskurs vom Vortag:
$4.50
Offen:
$4.5
24-Stunden-Volumen:
107.72K
Relative Volume:
0.48
Marktkapitalisierung:
$165.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+1.32%
1M Leistung:
-3.15%
6M Leistung:
+2.44%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.48
$4.65
1-Wochen-Bereich:
$4.38
$4.6508
52-Wochen-Spanne:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.61 | 162.04M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BioAge Labs to Present at Upcoming Investor Conferences - MarketScreener
Clinical-Stage Biotech BioAge Labs Announces Key Presentations at Citi and Morgan Stanley Healthcare Events - Stock Titan
BioAge Labs announces first participant dosed in Phase 1 trial of BGE-102 - MSN
BioAge commences dosing in trial of obesity treatment candidate BGE-102 - Yahoo Finance
Is BioAge Labs Inc. stock good for income investorsJuly 2025 Setups & Safe Investment Capital Preservation Plans - 선데이타임즈
Should I trade or invest in BioAge Labs Inc.Bear Alert & Technical Pattern Alert System - thegnnews.com
Can BioAge Labs Inc. Regain Lost Ground This Quarter2025 Buyback Activity & Weekly Top Stock Performers List - sundaytimes.kr
Market reaction to BioAge Labs Inc.’s recent newsBond Market & Verified High Yield Trade Plans - Newser
Should you hold or exit BioAge Labs Inc. nowWeekly Stock Report & Weekly Setup with High ROI Potential - Newser
BIOA FINAL DEADLINE: BioAge Labs Investors are Encouraged - GlobeNewswire
How BioAge Labs Inc. stock performs during market volatility2025 Growth vs Value & Daily Profit Maximizing Tips - beatles.ru
What institutional flow reveals about BioAge Labs Inc.July 2025 Levels & AI Based Buy and Sell Signals - Newser
BioAge Labs Reports Q2 2025 Financial Results and Progress - TipRanks
Earnings visualization tools for BioAge Labs Inc.July 2025 Analyst Calls & Real-Time Market Sentiment Reports - Newser
What’s the outlook for BioAge Labs Inc.’s sectorWeekly Gains Summary & Low Drawdown Investment Strategies - sundaytimes.kr
BioAge Labs: First Person Dosed in Phase 1 BGE-102 Trial - Lifespan Research Institute
BioAge Labs begins phase 1 trial of oral NLRP3 inhibitor for obesity - Investing.com Canada
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - MarketScreener
25% Weight Loss: BioAge's New Oral Drug Shows Breakthrough Results Combined with GLP-1s in Pre-Clinical Study - Stock Titan
BioAge Labs Inc. stock daily chart insightsWeekly Gains Summary & Weekly Watchlist for Consistent Profits - Newser
What data driven models say about BioAge Labs Inc.’s futureTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Is BioAge Labs Inc. a turnaround storyShort-Term Capital Growth Stocks - thegnnews.com
What is BioAge Labs Inc. s revenue forecast3x Potential Swing Trade Ideas - newsyoung.net
Q3 EPS Estimates for BioAge Labs Decreased by William Blair - Defense World
How to build a custom watchlist for BioAge Labs Inc.Real Time Growth Signal with Smart Setup - Newser
Real Time Data Flags Unusual Activity in BioAge Labs Inc.Consistent Gain Investment Strategies Emerge - beatles.ru
Smart tools for monitoring BioAge Labs Inc.’s price actionAI-Powered Stock Trend Movement Analysis - Newser
What makes BioAge Labs Inc. stock price move sharplyFree Growth Focused Entry Plan Suggestions - Newser
Cautious Outlook on BioAge Labs, Inc. Amid Uncertainties in Clinical Developments and Market Perception - TipRanks
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - The Motley Fool
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - Nasdaq
BioAge Labs, Inc. Advances Clinical Pipeline with BGE-102 Phase 1 Trial Set for 2H 2025 and Expands APJ Agonist Pipeline - Quiver Quantitative
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Q2 2025: BGE-102 on track for Phase 1, expanded APJ pipeline, strengthened discovery platform. - AInvest
Full technical analysis of BioAge Labs Inc. stockFree Fundamental Growth Stock Analysis - Newser
What are the technical indicators suggesting about BioAge Labs Inc.Maximize your returns with expert insights - Jammu Links News
What catalysts could drive BioAge Labs Inc. stock higher in 2025Dynamic investment growth - Jammu Links News
What is BioAge Labs Inc. company’s growth strategyHigh-margin investment plays - Jammu Links News
How does BioAge Labs Inc. compare to its industry peersDiscover undervalued stocks before they soar - Jammu Links News
Is BioAge Labs Inc. a growth stock or a value stockSkyrocketing returns - Jammu Links News
Should I hold or sell BioAge Labs Inc. stock in 2025Rapid market gains - Jammu Links News
What are the latest earnings results for BioAge Labs Inc.Navigate the market with precision tools - Jammu Links News
BioAge Labs Requests to Dismiss Class Action Filed by Investors - TradingView
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery - MSN
Published on: 2025-07-29 06:11:56 - beatles.ru
Price Channel Expanding on BioAge Labs Inc.’s ChartAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pande Vijay Satyanand | Director |
Oct 01 '24 |
Buy |
19.73 |
126,793 |
2,501,626 |
1,026,793 |
| Pande Vijay Satyanand | Director |
Oct 02 '24 |
Buy |
19.73 |
67,096 |
1,323,804 |
1,093,889 |
| Pande Vijay Satyanand | Director |
Oct 03 '24 |
Buy |
19.90 |
25,306 |
503,589 |
1,119,195 |
| Cormorant Asset Management, LP | Former 10% Owner |
Sep 27 '24 |
Buy |
18.00 |
450,000 |
8,100,000 |
1,629,529 |
| Pande Vijay Satyanand | Director |
Sep 27 '24 |
Buy |
18.00 |
900,000 |
16,200,000 |
900,000 |
| ENRIGHT PATRICK G | Director |
Sep 27 '24 |
Buy |
18.00 |
400,000 |
7,200,000 |
1,710,589 |
| HEALY JAMES | Director |
Sep 27 '24 |
Buy |
18.00 |
666,665 |
11,999,970 |
2,227,124 |
2.37%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):